Cencora (NYSE:COR) Reaches New 52-Week High at $243.97

Cencora, Inc. (NYSE:COR)’s share price hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $243.97 and last traded at $243.95, with a volume of 186868 shares changing hands. The stock had previously closed at $242.06.

Analysts Set New Price Targets

A number of brokerages recently commented on COR. StockNews.com upgraded shares of Cencora from a “buy” rating to a “strong-buy” rating in a research report on Thursday, February 1st. Mizuho increased their price target on shares of Cencora from $192.00 to $224.00 and gave the company a “neutral” rating in a research report on Monday, February 5th. Barclays began coverage on shares of Cencora in a research report on Wednesday, January 3rd. They issued an “overweight” rating and a $242.00 price objective on the stock. Leerink Partnrs reiterated an “outperform” rating on shares of Cencora in a report on Monday, February 26th. Finally, Wells Fargo & Company began coverage on Cencora in a research note on Thursday, December 14th. They issued an “equal weight” rating and a $213.00 target price on the stock. Three investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $214.90.

Cencora Price Performance

The company has a current ratio of 0.88, a quick ratio of 0.52 and a debt-to-equity ratio of 3.94. The stock has a market cap of $48.47 billion, a PE ratio of 26.47, a P/E/G ratio of 1.85 and a beta of 0.44. The business has a fifty day simple moving average of $233.55 and a two-hundred day simple moving average of $208.49.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, January 31st. The company reported $3.28 EPS for the quarter, beating the consensus estimate of $2.86 by $0.42. The business had revenue of $72.25 billion during the quarter, compared to analyst estimates of $68.81 billion. Cencora had a return on equity of 323.23% and a net margin of 0.69%. During the same quarter last year, the firm posted $2.71 earnings per share. Research analysts forecast that Cencora, Inc. will post 13.43 earnings per share for the current year.

Cencora Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, February 26th. Shareholders of record on Friday, February 9th were paid a dividend of $0.51 per share. This is an increase from Cencora’s previous quarterly dividend of $0.24. The ex-dividend date of this dividend was Thursday, February 8th. This represents a $2.04 dividend on an annualized basis and a dividend yield of 0.84%. Cencora’s dividend payout ratio (DPR) is currently 22.22%.

Insider Activity

In related news, EVP Elizabeth S. Campbell sold 6,977 shares of the company’s stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $238.12, for a total value of $1,661,363.24. Following the sale, the executive vice president now owns 8,246 shares in the company, valued at approximately $1,963,537.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, EVP Gina Clark sold 1,100 shares of the stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $230.48, for a total transaction of $253,528.00. Following the sale, the executive vice president now owns 24,802 shares in the company, valued at $5,716,364.96. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Elizabeth S. Campbell sold 6,977 shares of the business’s stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $238.12, for a total transaction of $1,661,363.24. Following the completion of the transaction, the executive vice president now owns 8,246 shares of the company’s stock, valued at $1,963,537.52. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 4,220,472 shares of company stock worth $993,554,798. Insiders own 15.80% of the company’s stock.

Institutional Trading of Cencora

Institutional investors and hedge funds have recently modified their holdings of the business. State of Wyoming raised its stake in Cencora by 2.6% during the 2nd quarter. State of Wyoming now owns 2,298 shares of the company’s stock valued at $442,000 after buying an additional 58 shares during the last quarter. Harbour Investments Inc. lifted its holdings in Cencora by 61.8% in the first quarter. Harbour Investments Inc. now owns 165 shares of the company’s stock valued at $26,000 after acquiring an additional 63 shares during the period. Horizon Family Wealth Inc. boosted its position in Cencora by 5.8% in the second quarter. Horizon Family Wealth Inc. now owns 1,438 shares of the company’s stock worth $277,000 after purchasing an additional 79 shares during the last quarter. Kinneret Advisory LLC grew its position in Cencora by 2.3% during the first quarter. Kinneret Advisory LLC now owns 4,406 shares of the company’s stock valued at $682,000 after buying an additional 98 shares during the period. Finally, Steward Partners Investment Advisory LLC grew its position in shares of Cencora by 0.5% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 20,174 shares of the company’s stock valued at $3,343,000 after acquiring an additional 103 shares during the period. Institutional investors own 97.52% of the company’s stock.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.